PMID- 34603281
OWN - NLM
STAT- MEDLINE
DCOM- 20211213
LR  - 20211214
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell 
      Migration.
PG  - 702453
LID - 10.3389/fimmu.2021.702453 [doi]
LID - 702453
AB  - Dendritic cells (DCs) are potent and versatile professional antigen-presenting 
      cells and central for the induction of adaptive immunity. The ability to migrate 
      and transport peripherally acquired antigens to draining lymph nodes for 
      subsequent cognate T cell priming is a key feature of DCs. Consequently, DC-based 
      immunotherapies are used to elicit tumor-antigen specific T cell responses in 
      cancer patients. Understanding chemokine-guided DC migration is critical to 
      explore DCs as cellular vaccines for immunotherapeutic approaches. Currently, 
      research is hampered by the lack of appropriate human cellular model systems to 
      effectively study spatio-temporal signaling and CCR7-driven migration of human 
      DCs. Here, we report that the previously established human neoplastic cell line 
      CAL-1 expresses the human DC surface antigens CD11c and HLA-DR together with 
      co-stimulatory molecules. Importantly, if exposed for three days to GM-CSF, CAL-1 
      cells induce the endogenous expression of the chemokine receptor CCR7 upon 
      encountering the clinically approved TLR7/8 agonist Resiquimod R848 and readily 
      migrate along chemokine gradients. Further, we demonstrate that CAL-1 cells can 
      be genetically modified to express fluorescent (GFP)-tagged reporter proteins to 
      study and visualize signaling or can be gene-edited using CRISPR/Cas9. Hence, we 
      herein present the human CAL-1 cell line as versatile and valuable cellular model 
      system to effectively study human DC migration and signaling.
CI  - Copyright (c) 2021 Uetz-von Allmen, Samson, Purvanov, Maeda and Legler.
FAU - Uetz-von Allmen, Edith
AU  - Uetz-von Allmen E
AD  - Biotechnology Institute Thurgau (BITg) at the University of Konstanz, 
      Kreuzlingen, Switzerland.
FAU - Samson, Guerric P B
AU  - Samson GPB
AD  - Biotechnology Institute Thurgau (BITg) at the University of Konstanz, 
      Kreuzlingen, Switzerland.
AD  - Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern, 
      Bern, Switzerland.
FAU - Purvanov, Vladimir
AU  - Purvanov V
AD  - Biotechnology Institute Thurgau (BITg) at the University of Konstanz, 
      Kreuzlingen, Switzerland.
FAU - Maeda, Takahiro
AU  - Maeda T
AD  - Department of Laboratory Medicine, Nagasaki University Graduate School of 
      Biomedical Sciences, Nagasaki, Japan.
FAU - Legler, Daniel F
AU  - Legler DF
AD  - Biotechnology Institute Thurgau (BITg) at the University of Konstanz, 
      Kreuzlingen, Switzerland.
AD  - Theodor Kocher Institute, University of Bern, Bern, Switzerland.
AD  - Department of Biology, University of Konstanz, Konstanz, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210916
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (CCR7 protein, human)
RN  - 0 (Receptors, CCR7)
SB  - IM
MH  - *Cell Line, Tumor
MH  - Cell Movement/*immunology
MH  - Dendritic Cells/*physiology
MH  - Humans
MH  - Receptors, CCR7/*metabolism
PMC - PMC8482423
OTO - NOTNLM
OT  - CCL19
OT  - CCL21
OT  - CRISPR/Cas9 mediated CCR7 knockout
OT  - cell migration
OT  - chemokine receptor CCR7
OT  - chemotaxis
OT  - expression of fluorescent reporter proteins
OT  - human dendritic cell line
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/05 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/01/01
CRDT- 2021/10/04 05:57
PHST- 2021/04/29 00:00 [received]
PHST- 2021/08/31 00:00 [accepted]
PHST- 2021/10/04 05:57 [entrez]
PHST- 2021/10/05 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.702453 [doi]
PST - epublish
SO  - Front Immunol. 2021 Sep 16;12:702453. doi: 10.3389/fimmu.2021.702453. eCollection 
      2021.